Most biotechs have long expensive trial phases to
Post# of 8462
Posted On: 12/09/2015 11:34:18 AM
Most biotechs have long expensive trial phases to get through before they'll ever make a dime of revenue, and going public helps these companies raise the capital necessary to make it to solvency. $GAHC seems to following similar paths. $ENDV $KBIO
http://finance.yahoo.com/news/why-gahc-biotec...00077.html
http://finance.yahoo.com/news/why-gahc-biotec...00077.html
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼